GlassScriptPhysician profile
Jillian L Hochfelder
NPI 1245473669
$2,630.22
in general payments reported to CMS, 2019-2025
19 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $172 · 2022: $120 · 2023: $595 · 2024: $650 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.99 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $535.05 | 2019-2025 | Nucala |
| Genzyme Corporation | $292.45 | 2019-2025 | |
| Csl Behring | $284.77 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Novartis Pharmaceuticals Corporation | $276.58 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $255.56 | 2019-2025 | Fasenra, Tezspire |
| Incyte Corporation | $125.57 | 2023 | Opzelura |
| Shire North American Group INC | $123.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.29 | 2020-2025 | Cuvitru |
| Regeneron Healthcare Solutions, INC. | $114.50 | 2019-2024 | Dupixent |
| Kaleo, INC. | $98.80 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $90.45 | 2024-2025 | Xembify |
| Genentech, INC. | $60.15 | 2022-2024 | Xolair |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Nestle Healthcare Nutrition INC. | $46.55 | 2022-2023 | |
| Genentech USA, INC. | $45.03 | 2024 | Xolair |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.95 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $29.40 | 2025 | Neffy |
| Leo Pharma INC. | $26.58 | 2025 | Anzupgo |
| Biocryst US Sales Co., LLC | $17.47 | 2024 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Hochfelder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.